Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders.
Botulinum Toxins, Type A
/ administration & dosage
Chronic Pain
/ drug therapy
Dose-Response Relationship, Drug
Female
Humans
Injections
Neuromuscular Agents
/ administration & dosage
Pelvic Pain
/ drug therapy
Prospective Studies
Spasm
/ drug therapy
Treatment Outcome
Vaginismus
/ drug therapy
Vulvar Diseases
/ drug therapy
Botulinum toxin
Chemodenervation
Chronic pelvic pain
Pelvic floor spasm
Pelvic pain
Vaginismus
Journal
International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
24
08
2018
accepted:
16
11
2018
pubmed:
9
1
2019
medline:
4
3
2020
entrez:
9
1
2019
Statut:
ppublish
Résumé
Botulinum toxin (BoNT) is increasingly used for pain, especially with muscle spasm. We describe our methodology for BoNT treatment of chronic pelvic pain (CPP) in women and place it in the context of the literature on techniques for this use. Databases were searched using terms "botulinum toxin," "pelvic pain," and "vaginismus." Reports on vaginismus/vulvodynia/vestibulodynia (included if pelvic floor muscles were injected) were grouped as "vaginismus/vulvar pain disorders" (V/VPD). We analyzed the type of report, condition, toxin serotype/brand, dose/dilution, muscle selection, guidance technique, and anesthesia. Publications from the same authors without unique information were combined for specific analyses. Thirty-eight reports had analyzable information; many lacked complete information. Most were open-label prospective reports; there were four technical reports, one randomized comparison of doses and one placebo-controlled study of efficacy. Pelvic floor muscles were approached transvaginally, transperineally or transgluteally. BoNT brand/dose/dilution varied widely. Muscle localization techniques included anatomical landmarks only, electromyography, electrical stimulation with/without ultrasound, and fluoroscopy/CT scanning. Papers discussing analgesia utilized general anesthesia, conscious sedation with/without topical/local anesthesia, topical/local agent alone or pudendal block before or after injection. Cumulatively, 58-100% of patients with CPP and 71-100% of those with V/VPD improved. Serious adverse events (transient fecal incontinence/constipation, urinary incontinence/retention) were more frequent with higher doses. BoNT can be safely and tolerably injected into pelvic floor muscles in women as an out-patient procedure. This study identifies methodological factors to be considered in future studies and the critical need for high-quality clinical trials for this emerging treatment.
Identifiants
pubmed: 30617506
doi: 10.1007/s00192-018-3831-z
pii: 10.1007/s00192-018-3831-z
doi:
Substances chimiques
Neuromuscular Agents
0
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1071-1081Références
J Reprod Med. 2006 Aug;51(8):635-41
pubmed: 16967634
Curr Rheumatol Rev. 2015;11(2):146-66
pubmed: 26088216
Hum Reprod Update. 2011 May-Jun;17(3):327-46
pubmed: 21106492
Sex Med. 2017 Jun;5(2):e114-e123
pubmed: 28363809
Female Pelvic Med Reconstr Surg. 2015 Sep-Oct;21(5):277-82
pubmed: 25900057
J Bodyw Mov Ther. 2008 Oct;12(4):371-384
pubmed: 19083696
Ther Adv Neurol Disord. 2017 Feb;10(2):127-135
pubmed: 28382110
Pain Med. 2018 Oct 1;19(10):2009-2015
pubmed: 29522121
Parkinsonism Relat Disord. 2011 Nov;17 Suppl 1:S28-33
pubmed: 21999893
J Sex Med. 2011 May;8(5):1287-90
pubmed: 21521483
Pain Manag. 2017 May;7(3):155-159
pubmed: 28073312
Aust N Z J Obstet Gynaecol. 2015 Dec;55(6):612-4
pubmed: 26224128
Int J Womens Health. 2014 May 02;6:437-49
pubmed: 24833921
J Psychosom Obstet Gynaecol. 2005 Jun;26(2):107-13
pubmed: 16050536
Obstet Gynecol. 2004 Nov;104(5 Pt 1):922-5
pubmed: 15516379
Obstet Gynecol. 2006 Oct;108(4):915-23
pubmed: 17012454
Obstet Gynecol. 2009 Aug;114(2 Pt 2):484-7
pubmed: 19622971
Female Pelvic Med Reconstr Surg. 2013 Sep-Oct;19(5):288-92
pubmed: 23982578
J Pain. 2005 May;6(5):333-7
pubmed: 15890635
J Reprod Med. 2006 Jun;51(6):467-70
pubmed: 16846084
Gynecol Obstet Invest. 2004;58(3):164-7
pubmed: 15249744
Obstet Gynecol. 2015 Mar;125(3):719-28
pubmed: 25730237
J Sex Med. 2011 Jun;8(6):1735-9
pubmed: 21477018
Lancet. 1997 Jan 25;349(9047):252-3
pubmed: 9014917
Ultrasound Obstet Gynecol. 2018 Mar;51(3):396-400
pubmed: 28557012
Toxins (Basel). 2018 Jun 01;10(6):
pubmed: 29857568
Eur Urol. 2013 Sep;64(3):431-9
pubmed: 23684447
Toxicon. 2013 Mar 1;63:83-7
pubmed: 23220489
Semin Reprod Med. 2017 Jan;35(1):88-97
pubmed: 28049214
Clin J Pain. 2011 Nov-Dec;27(9):755-63
pubmed: 21593667
Aust N Z J Obstet Gynaecol. 2004 Feb;44(1):46-50
pubmed: 15089868
Plast Reconstr Surg. 2009 Dec;124(6):455e-6e
pubmed: 19952618
Int J Impot Res. 2007 Jan-Feb;19(1):84-7
pubmed: 16728964
Am J Obstet Gynecol. 2012 Mar;206(3):e7-8
pubmed: 22381609
Int Urogynecol J. 2013 Sep;24(9):1429-34
pubmed: 23314224
Prog Neurobiol. 2014 Aug-Sep;119-120:39-59
pubmed: 24915026
Obstet Gynecol. 2009 Nov;114(5):1008-16
pubmed: 20168100
Investig Clin Urol. 2017 Mar;58(2):134-139
pubmed: 28261683
Curr Urol Rep. 2013 Oct;14(5):409-17
pubmed: 23943509
BJOG. 2005 Feb;112(2):247-9
pubmed: 15663593
J Headache Pain. 2017 Dec;18(1):38
pubmed: 28324318
Pain Physician. 2014 Mar-Apr;17(2):E141-7
pubmed: 24658485
Toxicon. 2018 Jun 1;147:120-128
pubmed: 29409817
J Forensic Sci. 2005 Jan;50(1):169-72
pubmed: 15831014